News

Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, announced it has raised $55 million in Series B financing, funds it will use for Phase II clinical…
Read More...

Pfizer Inc. and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis…
Read More...

Eureka Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ET140202 ARTEMIS T-cell therapy in…
Read More...

Cannassure Therapeutics announces its collaboration with Cannika Holdings, an agritech incubator specializing in cannabis innovation. Cannika will operate out of the Cannassure campus,…
Read More...

Genentech announced the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with…
Read More...

SGS announced that it has invested GBP 7.6 million in its facility in Glasgow, UK to expand the capabilities and capacity for testing cell banks and routine bulk harvest for vaccines,…
Read More...

Fresenius Kabi announced the immediate availability in the United States of Leucovorin Calcium Injection, USP, a medication indicated to counteract the toxicity and diminish the effects…
Read More...

Triphase Accelerator, together with its majority shareholder FACIT, announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5…
Read More...

The WIRB-Copernicus Group's (WCG) Clinical Services Division has partnered with Prudentia Group to deliver a comprehensive solution to enhance the quality, safety and regulatory…
Read More...

Horizon Discovery Group plc announces that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey (US), to develop and commercialise a…
Read More...

BioDuro and Advent International announced a partnership to support BioDuro's growth as a premier provider of integrated drug discovery, development and manufacturing services. Under…
Read More...

Orgenesis Inc. announced that its subsidiary, Masthercell Global Inc., is expanding into the United States and has executed a lease agreement to build a new 30,000 sq. ft manufacturing…
Read More...

Olon S.p.A. announced the acquisition of Capua BioServices S.p.A., a global provider of CDMO services in the field of microbial fermentation, as part of a continuing expansion of its…
Read More...

Concert Pharmaceuticals announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive…
Read More...

ArQule, Inc.’s partner, Basilea Pharmaceutica announced that it entered into a collaboration with Roche to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking…
Read More...

Following the recent U.S Food and Drug Administration (FDA) approval of the Prior Approval Supplement (PAS) for second-generation Andexxa, Portola Pharmaceuticals, Inc. and Lonza…
Read More...

Ferring Pharmaceuticals (U.S.) announced that it has appointed Sophie Opdyke, Pharm.D., MBA as Vice President, General Manager, Oncology, effective immediately. She most recently served…
Read More...

Ironwood Pharmaceuticals announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant…
Read More...

Rigel Pharmaceuticals announced that it has entered into an exclusive license and supply agreement with Spain-based Grifols to commercialize fostamatinib disodium hexahydrate in all…
Read More...

CAMP4 Therapeutics announced a research collaboration with Alnylam Pharmaceuticals focused on identifying new druggable targets to address an undisclosed rare disease of the liver with…
Read More...